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• Immune checkpoint blockade (ICB) therapies 
have shown promising results in treating a 
variety of cancer types. However, the median 
overall survival of triple negative breast cancer 
(TNBC) remains very low. 
• A new protein B7 homolog 3 (B7H3), or CD276, 
was found to be overexpressed in many cancer 
cells and have little to no expression on normal 
cells. 
• It initially was characterized as a costimulatory 
molecule promoting the activation of T cells but 
is now understood to act mainly as a coinhibitory 
molecule of the immune system.
• B7H3’s mechanism of action and receptor 
remain uncharacterized, but its preference for 
malignant cells offers hope for a new therapeutic 
approach with less toxicity and more efficiency.
• We performed immunohistochemistry to 
investigate B7H3 expression in TNBC primary 
tumors (n=49) and adjacent normal mammary 
tissue (n=30). The data was acquired and 
quantitated using Vectra-Polaris®, multi-
spectral imaging system
• Natural killer (NK) cells and T lymphocytes 
were isolated from buffy coats of healthy 
donors by Ficoll density gradient 
centrifugation.
• RFP-tagged B7H3+/- TNBC cell lines were co-
cultured with primary NK cells or T cells at 
different immune cell to target cells ratios. The 
cells were simultaneously incubated with 
different concentrations of novel anti-B7H3 
monoclonal antibodies (mAb) or chimeric 
antibodies (chAb) against a control antibody 
• Immune cell-mediated apoptosis and antibody-
dependent cytotoxic was measured by 
IncuCyte® live cell imaging system
• To determine the expression of B7H3 in 
primary TNBC tumors and measure the effect 
of novel anti-B7-H3 antibodies in the 
activation of NK cells and T lymphocytes 
against TNBC
Fig. 2. Addition of anti-B7H3 monoclonal antibodies promotes NK cell-mediated apoptosis in HCC38 RFP 
cells. More apoptosis can be seen with treatment of NK:TNBC cell ratio 8:1 + 10ug/ml mAb (yellow) 
versus control IgG (green) at 8 hours (b)
Fig. 4. Addition of anti-B7H3 monoclonal antibodies promote apoptosis by T lymphocytes in HCC38 RFP 
cells. An increase in killing can be seen with treatment of  T cells: TNBC cell ratio of 10:1 + 10ug/ml 
mAb (yellow) versus IgG control (green) in 6 hours (b). 
Fig. 3. Addition of anti-B7H3 chimeric antibodies promote ADCC in MCF7 RFP cells. A decrease in 
surviving cells can be seen with treatment of NK:TNBC cell ratio of 2:1 + 5ug/ml chAb (yellow) versus 







• B7H3 is overexpressed in TNBC cells
compared to healthy donors, validating it as a 
potential therapeutic target in patients
• Activation of NK cells is evident in figure 2 
as seen by the increased killing with our 
novel mAb compared to IgG control 
antibody. The antibody also enhanced T cell 
killing by blocking B7H3 as shown in figure 
4
• Figure 3 demonstrates the decreasing amount 
of live MCF7RFP cells as a result of 
treatment with the chimeric anti-B7H3 
antibody co-cultured with NK cells. This 
required a much lower dose of NK cells than 
the experiment with monoclonal antibodies. 
This is due to the activation of the ADCC 
mechanism. 
• The data suggests that our novel monoclonal 
and chimeric B7H3 blocking antibodies 
inhibit its immunomodulatory function and 
activate immune cells against TNBC cells
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Fig. 1. IHC assay shows higher B7H3 expression in tumor tissue than normal mammary tissue
• Fang, J., Chen, F., Liu, D., Gu, F., Chen, Z., 
& Wang, Y. (2020). Prognostic value of 
immune checkpoint molecules in breast 
cancer. Bioscience reports, 40(7), 
BSR20201054. 
https://doi.org/10.1042/BSR20201054
• Flem-Karlsen, K., Fodstad, Ø., & Nunes-
Xavier, C. E. (2020). B7-H3 Immune 
Checkpoint Protein in Human 




I would like to thank the Department of 
Leukemia and all members of the Battula Lab. 
Thank you to the donors at the University of
Notre Dame for making this research possible. 
